Outset Medical (NASDAQ:OM) & Heyu Biological Technology (OTCMKTS:HYBT) Financial Analysis

Heyu Biological Technology (OTCMKTS:HYBT) and Outset Medical (NASDAQ:OM) are both small-cap computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

Valuation and Earnings

This table compares Heyu Biological Technology and Outset Medical’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heyu Biological Technology	$80,000.00	451.71	-$270,000.00	N/A	N/A
Outset Medical	$130.38 million	1.53	-$172.80 million	($3.38)	-1.14

Heyu Biological Technology has higher earnings, but lower revenue than Outset Medical.

Analyst Ratings

This is a summary of recent recommendations for Heyu Biological Technology and Outset Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heyu Biological Technology	0	0	0	0	N/A
Outset Medical	1	2	3	0	2.33

Outset Medical has a consensus price target of $5.42, suggesting a potential upside of 40.69%. Given Outset Medical’s higher probable upside, analysts plainly believe Outset Medical is more favorable than Heyu Biological Technology.

Profitability

This table compares Heyu Biological Technology and Outset Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Heyu Biological Technology	-453.55%	-6.43%	-4.43%
Outset Medical	-134.93%	-120.67%	-51.09%

Risk & Volatility

Heyu Biological Technology has a beta of -17.74, meaning that its share price is 1,874% less volatile than the S&P 500. Comparatively, Outset Medical has a beta of 2, meaning that its share price is 100% more volatile than the S&P 500.

Summary

Outset Medical beats Heyu Biological Technology on 5 of the 9 factors compared between the two stocks.

About Heyu Biological Technology

Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.

About Outset Medical

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.